longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Alkermes

ALKS

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 109.83, above the reasonable range, cheaper than 5.12% of the time in the past 3 years, and the industry ranks 59/602, the industry Median -2.43.

109.83xP/E
$43.29Stock price
$0.39Earnings per share
109.83xP/E
Stock price$43.29Earnings per share$0.39

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
14.81x
Typical range
13.14x–21.19x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
PTGXUSProtagonist Therap
113.22x326.86%$9.39B
ALKSUSAlkermes
109.83x135.68%$7.26B
MDXGUSMiMedx
115.32x153.13%$719.46M
ICCCUSImmuCell
115.23x--$90.73M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.